Intermittent Androgen Deprivation for Locally Advanced and Metastatic Prostate Cancer: Results from a Randomised Phase 3 Study of the South European Uroncological Group
- 1 June 2009
- journal article
- research article
- Published by Elsevier in European Urology
- Vol. 55 (6) , 1269-1277
- https://doi.org/10.1016/j.eururo.2009.02.016
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Intermittent androgen blockade should be regarded as standard therapy in prostate cancerNature Clinical Practice Oncology, 2008
- Using PSA to Guide Timing of Androgen Deprivation in Patients with T0–4 N0–2 M0 Prostate Cancer not Suitable for Local Curative Treatment (EORTC 30891)European Urology, 2007
- EAU Guidelines on Prostate CancerEuropean Urology, 2007
- International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta‐analysis of 1446 patientsBJU International, 2007
- Cellular Changes in Prostate Cancer Cells Induced by Intermittent Androgen SuppressionEuropean Urology, 2006
- Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancerEuropean Journal Of Cancer, 2006
- Intermittent Maximal Androgen Blockade in Patients with Metastatic Prostate Cancer: An EORTC Feasibility StudyEuropean Urology, 2003
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour modelThe Journal of Steroid Biochemistry and Molecular Biology, 1996
- A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing RiskThe Annals of Statistics, 1988